The REMODULIN (treprostinil sodium) Injection brand, founded in 2008 (United States), from 16 sister brands and 2214 competing brands. REMODULIN (treprostinil sodium) Injection is owned by United Therapeutics Co., listed on the stock exchange of New York REMODULIN (treprostinil sodium) Injection is part of the Biotechnology activity sector.

REMODULIN (treprostinil sodium) Injection is a brand of United Therapeutics Co. (UTHR) Share price

International deposit : 2008 Business sector Biotechnology

Share price and profitability of the share United Therapeutics Co. (REMODULIN (treprostinil sodium) Injection)

Buy United Therapeutics Co. share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested USD 237.00

Portfolio valuation
United Therapeutics Co. (REMODULIN (treprostinil sodium) Injection) over 5 years* USD 546.14

Stock market history United Therapeutics Co. (REMODULIN (treprostinil sodium) Injection)

*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances

Other brands
United Therapeutics Co.

See more brands of United Therapeutics Co.

Rival brands
REMODULIN (treprostinil sodium) Injection

NOTABLE LABS
NOTABLE LABS
Roivant
Roivant
Valerio Therapeutics
Valerio Therapeutics
INVERSAGO
INVERSAGO
Terns Pharma
Terns Pharma
Vaxcyte
Vaxcyte
OTHER RIVAL BRANDS

Top Popularity Web

See the full ranking
Desirable brands that generate Pricing Power and therefore stock market performance
Desirable brands that generate Pricing Power and therefore stock market performance

Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.

Read more
MORE NEWS